Improving Genomics-based Personalized Cancer Medicine

The Bivona Lab engages in studies linking the bench with the bedside that investigate the molecular pathogenesis of human cancers, with a primary focus on lung cancer (e.g. please see Bivona TG, et al Nature 471, 523-526, 24 March 2011). Our objective is to enhance responses in patients to treatments that target aberrant signal transduction pathways that drive tumor growth.

We use emerging, multidisciplinary, and integrative functional genomics methodologies, highly relevant cell line and tumor model systems, and appropriate human tumor specimens to design novel, rational therapeutic strategies and to translate our findings into clinical applications. Our laboratory investigations often lead to clinical trials testing novel, molecularly-targeted cancer therapies that are aimed at improving the survival of genetically-defined subsets of patients with lung and other lethal cancers.

Gene Breakthroughs Spark a Revolution in Lung Cancer Treatment

Dr.Trever Bivona tells the Wall Street Journal how precision medicine is leading to gene breakthroughs and a revolution in the treatment of lung cancer, the goal - pairing a drug with the specific mutation fueling a patient’s disease. (Also pictured is Bivona Lab research specialist Elton Chan).

Bivona on Personalized Lung Cancer TherapyVisit the Bivona Lab YouTube Channel

Youtube png

Recent Publications

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas.
Cancer cell, Apr-13-2015; 274: 533-46.
Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer.
Cell reports, Apr-07-2015; 111: 98-110.  Epub 2015 Apr 2.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Nature genetics, Mar-01-2015; 473: 250-6.  Epub 2015 Feb 09.
Pazarentzos E, Bivona TG
Adaptive stress signaling in targeted cancer therapy resistance.
Oncogene, Feb-23-2015; [Epub ahead of print].
Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
PloS one, [epublish] 103: e0119832.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nature genetics, Aug-01-2012; [epublish] 448: 852-60.
Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Proceedings of the National Academy of Sciences of the United States of America, Nov-22-2011; 10847: 19024-9.  Epub 2011 Nov 7.
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Nature, Mar-24-2011; 4717339: 523-6.
Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research, Mar-01-2011; 175: 1160-8.  Epub 2011 Feb 22.
Quatela SE, Sung PJ, Ahearn IM, Bivona TG, Philips MR
Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis.
Methods in enzymology, 439: 87-102.
Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez de Castro I, Li C, Thompson CB, Cox AD, Philips MR
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.
Molecular cell, Feb-17-2006; 214: 481-93.
View all Publications »

News and Events

View all News»